{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:06:16Z","timestamp":1771603576720,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ymgme.2018.11.004","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T17:52:08Z","timestamp":1541785928000},"page":"157-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy"],"prefix":"10.1016","volume":"126","author":[{"given":"Kunal C.","family":"Potnis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren B.","family":"Flueckinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine I.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jariya","family":"Upadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald P.","family":"Frush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya S.","family":"Kishnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ymgme.2018.11.004_bb0005","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10409239009090616","article-title":"Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease","volume":"25","author":"Grabowski","year":"1990","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"issue":"S1","key":"10.1016\/j.ymgme.2018.11.004_bb0010","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1259\/bjr.75.suppl_1.750002","article-title":"Skeletal aspects of Gaucher disease: a review","volume":"75","author":"Wenstrup","year":"2002","journal-title":"Br. J. Radiol."},{"issue":"6","key":"10.1016\/j.ymgme.2018.11.004_bb0015","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"issue":"19","key":"10.1016\/j.ymgme.2018.11.004_bb0020","first-page":"1","article-title":"Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report","volume":"11","author":"Ceravolo","year":"2017","journal-title":"J. Med. Case Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.004_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1067\/S0022-3476(03)00302-0","article-title":"Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3","volume":"143","author":"Goker-Alpan","year":"2003","journal-title":"J. Pediatr."},{"issue":"S1","key":"10.1016\/j.ymgme.2018.11.004_bb0030","first-page":"S19","article-title":"Long-term treatment outcomes in Gaucher disease","volume":"90","author":"Charrow","year":"2015","journal-title":"Am. J. Hepatol."},{"key":"10.1016\/j.ymgme.2018.11.004_bb0035","series-title":"Gaucher Disease","author":"Pastores","year":"2000"},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.004_bb0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1023\/A:1005495229655","article-title":"Enzyme replacement therapy in type III Gaucher disease","volume":"22","author":"Tylki-Szymanska","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.004_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","article-title":"Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry","volume":"33","author":"Tylki-Szymanska","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2018.11.004_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.ymgme.2018.11.004_bb0055","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"S1","key":"10.1016\/j.ymgme.2018.11.004_bb0060","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"Zimran","year":"2014","journal-title":"Pediatr. Endocrinol. Rev."},{"issue":"21","key":"10.1016\/j.ymgme.2018.11.004_bb0065","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2014macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.004_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5\u202fyears of treatment: a report from the Gaucher Registry","volume":"113","author":"Weinreb","year":"2002","journal-title":"Am. J. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2018.11.004_bb0075","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3324\/haematol.12651","article-title":"Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy","volume":"93","author":"de Fost","year":"2008","journal-title":"Haematologia"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2018.11.004_bb0080","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s004399900076","article-title":"Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation","volume":"105","author":"Ida","year":"1999","journal-title":"Hum. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.004_bb0085","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","article-title":"Therapeutic approaches to bone pathology in Gaucher disease: past, present and future","volume":"104","author":"Goker-Alpan","year":"2011","journal-title":"Mol. Genet. Metab."},{"issue":"11","key":"10.1016\/j.ymgme.2018.11.004_bb0090","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/jbmr.5650111125","article-title":"Bone density in Type 1 Gaucher disease","volume":"11","author":"Pastores","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.004_bb0095","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/MD.0b013e3182057be4","article-title":"Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy","volume":"90","author":"Deegan","year":"2011","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.ymgme.2018.11.004_bb0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"Mistry","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.ymgme.2018.11.004_bb0105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1006\/bcmd.1996.0016","article-title":"Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement","volume":"22","author":"Elstein","year":"1996","journal-title":"Blood Cell Mol. Dis."},{"issue":"May 1999","key":"10.1016\/j.ymgme.2018.11.004_bb0110","first-page":"201","article-title":"Risk factors for osteonecrosis in patients with type 1 Gaucher's disease","volume":"362","author":"Rodrigue","year":"1999","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"19","key":"10.1016\/j.ymgme.2018.11.004_bb0115","first-page":"1","article-title":"Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports","volume":"12","author":"Amato","year":"2018","journal-title":"J. Med. Case Rep."},{"issue":"12","key":"10.1016\/j.ymgme.2018.11.004_bb0120","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3324\/haematol.2009.008078","article-title":"Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project","volume":"94","author":"Giraldo","year":"2009","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ymgme.2018.11.004_bb0125","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.clinthera.2007.08.006","article-title":"Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies","volume":"29","author":"Pastores","year":"2007","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ymgme.2018.11.004_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur. J. Internal Med."},{"key":"10.1016\/j.ymgme.2018.11.004_bb0135","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease","volume":"9","author":"Bennett","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"10","key":"10.1016\/j.ymgme.2018.11.004_bb0140","doi-asserted-by":"crossref","first-page":"E448","DOI":"10.1002\/ajh.24486","article-title":"Skeletal involvement in Gaucher disease: an observational multicenter study of prognostic factors in the Argentine Gaucher disease patients","volume":"91","author":"Drelichman","year":"2016","journal-title":"Am. J. Hematol."},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2018.11.004_bb0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ymgme.2016.11.006","article-title":"Gaucher disease: Progress and ongoing challenges","volume":"120","author":"Mistry","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"1","key":"10.1016\/j.ymgme.2018.11.004_bb0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13023-017-0627-z","article-title":"Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease","volume":"12","author":"Andrade-Campos","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"3","key":"10.1016\/j.ymgme.2018.11.004_bb0155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bcmd.2007.06.015","article-title":"Molecular characterization of type 3 (neuronopathic) Gaucher disease in Thai patients","volume":"39","author":"Suwannarat","year":"2007","journal-title":"Blood Cell Mol. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218303767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719218303767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T07:16:46Z","timestamp":1549091806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719218303767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1096719218303767"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.004","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2018.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}